Friday, September 29, 2023
Friday, September 29, 2023

Contact us 561.316.3330

KA Imaging’s X-ray Detector Allows Dual Energy to Be Taken to the Bedside

July 9, 2020

KA Imaging notes: For the first time, practitioners will be able to leverage dual-energy x-ray technology in a portable system. Canadian manufacturer KA Imaging is getting ready to launch Reveal, the world’s first dual-energy x-ray detector that can be taken to the bedside.

KA Imaging President and CEO Amol Karnick notes, “Due to the infectious nature of COVID-19, bringing patients into a fixed radiology room can sometimes be risky.” He added, “Current dual-energy systems are all fixed and Reveal overcomes the limitation of a fixed room by providing a world-first portable dual-energy solution. Reveal provides radiologists with an unobstructed view of the lungs by removing the bones in an x-ray image.”

The FDA 510(k) pending detector works with a single exposure. Unlike fixed dual-energy solutions, Reveal’s technology enables bone and soft tissue differentiation with no motion artifact. “Our patented technology also allows lateral and oblique dual-energy views for the first time”, explains Dr. Karim S Karim, CTO at KA Imaging.

Whereas fixed dual-energy systems can cost as high as half a million dollars, KA Imaging’s Reveal is highly affordable at less than ¼ of this price.

“If a hospital requires dual-energy X-ray for COVID-19, you can simply replace any older CR plate or digital fixed or portable detector with Reveal”, says Amol.

Clinical trials

The company is planning clinical trials globally to demonstrate the efficacy of Reveal in triaging COVID-19 and other imaging tasks in the Emergency Room and Intensive Care Units. One of them is expected to begin in Toronto by August. “The world needs affordable and effective portable bedside diagnostics now, and Reveal is a solution that can provide tremendous value for clinicians, hospitals and government”, emphasizes Karim.

Reveal is also being tested on patients with lung cancer. Grand River Hospital (Kitchener, Ontario, Canada) was the first to test the technology. More than 20 patients have been imaged with Reveal, with promising initial results.

ECR

Radiologists globally can learn more about Reveal at the European Congress of Radiology (ECR) from July 15th to 19th. Due to the pandemic, the conference will be held online. KA Imaging is part of the virtual exhibition.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy